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AbsTrACT
background international research has focused on 
screening and mass media campaigns to promote earlier 
patient presentation and detect lung cancer earlier. this 
trial tested the effect of a behavioural intervention in 
people at increased risk of lung cancer on help-seeking 
for respiratory symptoms.
Methods Parallel, individually randomised controlled 
trial. eligible participants were long-term smokers 
with at least 20 pack-years, aged 55 and above. the 
cHeSt intervention entailed a consultation to discuss 
and implement a self-help manual, followed by self-
monitoring reminders to encourage help-seeking for 
respiratory symptoms. the control group received a brief 
discussion about lung health. Both groups had baseline 
spirometry. telephone randomisation was conducted, 
1:1, stratified Medical research council (Mrc) dyspnoea 
score and general practice. Participants could not be 
blinded; data extraction and statistical analyses were 
performed blinded to group assignment. the primary 
outcome was respiratory consultation rates.
results We randomised 551 participants (274 
intervention, 277 control) from whom the primary 
outcome was determined for 542 (269 intervention, 273 
control). there was a 40% relative increase in respiratory 
consultations in the intervention group: (adjusted rates 
(95% ci) intervention 0.57 (0.47 to 0.70), control 
0.41 (0.32 to 0.52), relative rate 1.40 (1.08 to 1.82); 
p=0.0123). there were no significant differences in time 
to first respiratory consultation, total consultation rates 
or measures of psychological harm. the incremental cost-
effectiveness ratio was $a1289 per additional respiratory 
consultation.
Conclusions a behavioural intervention can 
significantly increase consulting for respiratory symptoms 
in patients at increased risk of lung cancer. this 
intervention could have an important role in primary care 
as part of a broader approach to improve respiratory 
health in patients at higher risk.
Trial registration number australian new Zealand 
clinical trial registry (1261300039 3752). this was 
registered pre-results.
InTroduCTIon
Lung cancer is the most common cancer world-
wide and most common cause of cancer deaths.1 
In Australia, there will be an estimated 12 741 
new cases and 9198 deaths due to lung cancer in 
2018.2 Although there have been recent improve-
ments in outcomes for lung cancer, 5-year survival 
in Australia is only 16%2 and less than 10% in the 
UK.3 This is primarily because most patients are 
diagnosed when curative surgical treatment is not 
possible.3 4
There is growing evidence that time to diagnosis 
in symptomatic patients is associated with clinical 
outcomes for lung cancer.5 6Patient presentation 
to healthcare and initial management in primary 
care are key determinants of outcomes of patients 
with cancer.7 The Model of Pathways to Treatment 
describes symptom appraisal and help-seeking 
intervals as key timepoints along the cancer diag-
nostic pathway which contribute to overall time to 
diagnosis.8 9 Several studies have explored symptom 
appraisal and help-seeking in people recently diag-
nosed with lung cancer, identifying factors contrib-
uting to later presentation to healthcare. These 
include limited awareness of cancer symptoms, fear 
of cancer,10 concerns about wasting their own and 
general practitioners (GPs)’ time,11 stoicism12 13 and 
stigma around smoking.14 15 Current smokers are 
Key messages
What is the key question?
 ► Can a behavioural intervention, delivered in 
primary care, to patients at increased risk of 
lung cancer increase consulting for respiratory 
symptoms as an approach to reducing time to 
diagnose lung cancer?
What is the bottom line?
 ► The CHEST intervention significantly increased 
respiratory consultation rates in this population, 
without causing psychological harm, but there 
was no significant reduction in time to first 
presentation.
Why read on?
 ► This is the largest trial to date to test a tailored 
behavioural approach to reduce diagnostic 
delay for lung cancer. This targeted approach 
could be an alternative to mass media symptom 
awareness campaigns and support early 
intervention to improve respiratory health in 
long-term smokers in primary care.
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more likely to experience respiratory symptoms but less likely 
to consult about them.16 Studies in rural Western Australia have 
found that normalisation of respiratory symptoms is common, 
especially in those with respiratory comorbidities, with median 
patient delays to seek help of 50–80 days.17 18 These times should 
be compared with lung cancer median volume doubling times of 
98 days suggesting such delays could be clinically significant.19
The US National Lung Cancer Screening Trial found a 20% 
relative reduction in lung cancer mortality from annual low-dose 
CT,20 but the limited cost-effectiveness21 and feasibility of imple-
menting national lung cancer screening programmes22 means that 
other approaches to timely diagnosis of lung cancer are needed. 
The search for useful biomarkers of lung cancer shows promise, 
but is still at the validation stage.23 An alternative strategy is to 
attempt to diagnose lung cancer earlier through prompt recog-
nition and investigation of symptoms suggestive of the disease, 
particularly in those at higher risk of lung cancer.
Mass media campaigns to raise symptom awareness have 
shown variable evidence of effect. Data from the ‘Be Clear on 
Cancer’ campaigns in England, have suggested potentially useful 
short-term effects including increased presentations to general 
practice and detection of earlier stage lung cancer, but these 
are based on comparisons with historical control data.24 A trial 
in rural Western Australia of a mass media campaign, which 
included lung cancer symptom awareness, failed to demon-
strate an effect on time of presentation to healthcare or time to 
diagnosis.17
Instead of mass media approaches, more targeted interventions 
could promote earlier presentation to healthcare in individuals at 
increased risk of lung cancer. The CHEST Trial in Scotland was 
the first to show preliminary evidence that this approach could 
alter overall consulting patterns in this population.25 In that trial, 
a theoretically based intervention delivered in primary care to 
patients at increased risk of lung cancer significantly increased 
the overall consultation rate by 15%; it was not powered to 
detect differences in respiratory consultations.
We have adapted the Scottish CHEST intervention for an 
Australian population. While maintaining its core theoretical 
elements, we modified the language and format of the self-help 
manual and expanded approaches to prompt symptom moni-
toring. We report the results of the CHEST Australia Trial which 
aimed to test the modified CHEST Intervention in an Australian 
primary care population and measure its effect on consultation 
rates for respiratory symptoms.
MeThods
As we have published the trial protocol,26 we report the methods 
here in brief.
Trial design
Individually randomised controlled trial conducted in 11 general 
practices in Perth, Western Australia, and 6 in Melbourne, 
Victoria, Australia.
Participants
Eligible participants were long-term smokers with at least 20 
pack-years, aged 55 and above, including ex-smokers if their 
cessation date was less than 15 years ago. Participants were able 
to read and write English and give informed consent. Exclu-
sion criteria included severe psychiatric or cognitive disorder or 
previous diagnosis of lung cancer.
Patients who potentially met eligibility criteria were identified 
from the general practice electronic medical record using the 
Canning data extraction software ( www. canningtool. com. au). 
They were invited to participate in the study by letter from their 
general practice. Invitations included a patient information sheet 
and expression of interest form, which included four screening 
questions to assess smoking pack-years. Non-responders were 
followed up after 2 weeks with a reminder postcard. Eligible 
patients returning an expression of interest form were followed 
up by telephone to make a trial appointment at their general 
practice. Randomisation was performed after completion of 
baseline data and written informed consent had been obtained.
Intervention
A trained researcher performed spirometry and then guided the 
participant through a self-help manual, entitled Chest Symptoms 
that Call for Action.27 The key objectives of the manual were 
to: increase the salience and personal relevance of symptoms, 
improve knowledge of symptoms by introducing chest disease 
prototypes, reinforce the benefits of early intervention in lung 
cancer and other chest disease, and sanction early consultation. 
‘If-then’ action plans were developed with the participant, linked 
to symptom checklists, and ‘If-then’ coping plans discussed to 
tackle barriers to consultation. A range of monthly prompts to 
monitor current symptoms were tailored to individual prefer-
ences, including SMS and email reminders, postcards, phone 
calls and fridge magnets.
Control
A trained researcher performed spirometry and then had a brief 
general discussion about lung health. This was designed as an 
attention control and to increase overall engagement in the trial 
for control participants. Participants then received usual care at 
their general practice.
In both trial groups, the results of the spirometry were sent to 
the participant’s GP for follow-up according to usual practice.
outcomes and measures
The primary outcome of this trial was consultation rates 
for respiratory symptoms. Data on consultations in the year 
before the trial and for 12 months after the consultation were 
collected through audit of GP records. This was a phase II trial 
of a complex intervention28; our outcomes were designed to test 
whether the intervention has the potential to facilitate the early 
detection of lung cancer by evaluating its effect across a range of 
intermediate endpoints.
Additional measures included
1. Demographics and clinical variables: age, gender, marital sta-
tus, postcode, highest education level, occupation, Medical 
Research Council (MRC) Dyspnoea Scale29 and lung func-
tion at baseline only.
2. Self-efficacy for consulting without delay: a 10-item self-com-
pleted scale summed to score 10–100.25
3. Knowledge of symptoms of lung disease: a 21-item self-com-
pleted checklist of possible symptoms expressed as a percent-
age correctly selected as associated with chest disease.25
4. Symptom appraisal and help-seeking intervals measured 
using the SYMPTOM instrument (lung cancer version), a 
self-completed questionnaire that obtains data on presenting 
symptoms and their duration prior to consultation.30 Month-
ly electronic searches of the GP medical records identified 
recent respiratory consultations. Participants were sent a 
SYMPTOM questionnaire to complete about symptoms re-
lating to that consultation.
363Emery JD, et al. Thorax 2019;74:362–370. doi:10.1136/thoraxjnl-2018-212506
 o
n
 20 M
arch 2019 by guest. Protected by copyright.
http://thorax.bmj.com/
Thorax: first published as 10.1136/thoraxjnl-2018-212506 on 10 January 2019. Downloaded from 
Lung cancer
Figure 1 Trial flow chart. GP, general practitioner.
5. Hospital Anxiety and Depression Scale (HADS).31
6. Cancer-worry scale: a 6-item self-completed scale, adapted 
from the breast cancer worry scale and validated in the Scot-
tish CHEST Trial.25 32
7. Quality of life using the Assessment of Quality of Life 
(AQoL-8D).33
8. Heath service utilisation: in addition to the primary measure 
of consultation rates for respiratory symptoms, total general 
practice consultation rates, chest X-ray requests and refer-
rals to respiratory physicians were captured through audit of 
general practice medical records. Participants consented to 
access to their Medicare claims data (Pharmaceutical Benefits 
Scheme (PBS) and Medicare Benefits Schedule (MBS)) ob-
tained from the Department of Human Services. Medicare is 
the publicly funded universal healthcare system in Australia. 
Claims data provided more complete information about vis-
its to other general practices, including prescribing, investi-
gations and referrals arising from these.
Participant-completed measures were collected at base-
line, 1 and 12 months, with the exception of the SYMPTOM 
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Table 1 Baseline characteristics
Characteristic Level Intervention (n=274)
Control
(n=277)
Age: mean (SD) (n) 64.38 (9.8) (274) 64.07 (10.64) (277)
Sex Female 117 (42.7%) 114 (41.2%)
Male 157 (57.3%) 163 (58.8%)
FEV1: mean (SD) (n) 80.90 (21.65) (273) 81.63 (20.51) (276)
Smoking pack-years: mean (SD) (n) 45.18 (23.84) (274) 45.99 (24.4) (277)
Smoking status Ex-smoker 168 (61.3%) 148 (53.4%)
Current 106 (38.7%) 129 (46.6%)
Comorbidities Cardiovascular 100 (36.5%) 115 (41.5%)
Respiratory 90 (32.8%) 89 (32.1%)
Psychiatric 44 (16.1%) 41 (14.8%)
Diabetes 28 (10.2%) 35 (12.6%)
Other 92 (33.6%) 92 (33.2%)
Respiratory consultations from 12 months to baseline: mean (SD) (n) 0.86 (1.62) (269) 0.76 (1.25) (273)
All consultations from 12 months to baseline: mean (SD) (n) 9.06 (7.49) (270) 9.11 (7.70) (273)
Accommodation Own your home 204 (74.5%) 212 (76.5%)
Rent your home 50 (18.2%) 33 (11.9%)
Other (please specify below) 20 (7.3%) 22 (7.9%)
Missing 0 10 (3.6%)
Education Year 11 or below 86 (31.4%) 89 (32.1%)
Year 12 or equivalent 40 (14.6%) 38 (13.7%)
Trade/apprenticeship 29 (10.6%) 39 (14.1%)
Tertiary certificate/diploma 49 (17.9%) 57 (20.6%)
Undergraduate university degree 24 (8.8%) 17 (6.1%)
Postgraduate university degree 17 (6.2%) 12 (4.3%)
Other (please specify) 26 (9.5%) 17 (6.1%)
Missing 3 (1.1%) 8 (2.9%)
Living arrangements On your own 70 (25.5%) 70 (25.3%)
With a partner/spouse 166 (60.6%) 166 (59.9%)
With other family 32 (11.7%) 28 (10.1%)
Other (please specify below) 6 (2.2%) 5 (1.8%)
Missing 0 8 (2.9%)
Occupation (more than one can apply) Retired 85 (31.0%) 98 (35.4%)
Caring for dependent relative 14 (5.1%) 16 (5.8%)
Voluntary worker 20 (7.3%) 14 (5.1%)
Unemployed 52 (19.0%) 63 (22.7%)
Student 8 (2.9%) 3 (1.1%)
Looking after home/family 43 (15.7%) 48 (17.3%)
Disabled/unable to work 21 (7.7%) 22 (7.9%)
instrument as already described. Health service utilisation data 
were collected at 12 months from an audit of general practice 
medical records and obtaining Medicare claims data.
sample size
Data from the Scottish trial was used to inform power calcula-
tions.25 Assuming that the primary endpoint of consultations for 
respiratory symptoms follows a Poisson distribution, and that the 
expected average rate over 12 months in the study population 
would be 1.06 for control patients and 25% higher for inter-
vention patients, a sample of 534 would provide at least 80% 
power to reject the null hypothesis of no difference between the 
groups at the two-sided 5% level of significance. Accounting for 
the same attrition rate observed in the Scottish CHEST trial, we 
required a total sample of 550 participants.
randomisation
Those who met the eligibility criteria and who consented to 
participate were randomised 1:1 to either the control or inter-
vention. Randomisation was performed using a centralised inde-
pendent telerandomisation system managed by the National 
Health and Medical Research Council (NHMRC) Clinical Trials 
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Table 2 Respiratory and total consultations at 12 months
Characteristic Level
Intervention
(n=274)
Control
(n=277)
Mean respiratory 
consultations during
12-month follow-up 
(SD) (n)
0.67 (1.01) (269) 0.47 (0.78) (273)
Number of respiratory 
consultations during 
12-month follow-up 0 162 (59.1%) 184 (66.4%)
1 59 (21.5%) 58 (20.9%)
2 27 (9.9%) 22 (7.9%)
3 17 (6.2%) 9 (3.2%)
4 3 (1.1%) 0
5 1 (0.4%) 0
Missing 5 (1.8%) 4 (1.4%)
Mean total 
consultations during 
12-month follow-up 
(SD) (n)
9.05 (7.53) (268) 8.98 (8.14) (273)
At least one 
consultation during 
12-month follow-up No 21 (7.7%) 25 (9.0%)
Yes 247 (90.1%) 248 (89.5%)
Missing 6 (2.2%) 4 (1.4%)
Table 3 Secondary analysis of respiratory consultations adjusting for 
other baseline covariates
Covariates in negative 
binomial model
relative rate adjusted for 
covariate (95% CI)
Treatment group only 1.42 (1.08 to 1.87), p=0.0118
GP site plus the following 
covariate:
P-value for
covariate listed
  Respiratory consultations 
from 12 months to baseline
1.35 (1.04 to 1.74), p=0.0227 <0.0001
  Pack-years 1.40 (1.07 to 1.82), p=0.0125 0.2513
  Age 1.40 (1.07 to 1.81), p=0.0128 0.0122
  FEV1 1.37 (1.06 to 1.77), p=0.0159 <0.0001
  Gender 1.40 (1.08 to 1.83), p=0.0115 0.3145
  Smoker 1.39 (1.07 to 1.82), p=0.0142 0.7077
  MRC dyspnoea (1–2 vs 3–4) 1.41 (1.08 to 1.83), p=0.0110 0.0728
  Cardiovascular comorbidity 1.37 (1.05 to 1.78), p=0.0188 0.0756
  Respiratory comorbidity 1.38 (1.08 to 1.78), p=0.0112 <0.0001
  Psychiatric comorbidity 1.40 (1.08 to 1.81), p=0.0100 0.9965
  Diabetes 1.40 (1.08 to 1.83), p=0.0116 0.4836
  Other comorbidity 1.41 (1.08 to 1.84), p=0.0103 0.2033
GP, general practitioner.
Centre, based at the University of Sydney. Stratifying variables 
for randomisation were MRC dyspnoea score (scores 1–3 and 
4–5) and general practice recruitment site.
blinding
Outcomes assessed by self-report obviated the need for researcher 
blinding. For the extraction and analysis of health service utili-
sation data, research staff were blinded to group assignment. All 
statistical analyses were performed blinded to group assignment.
statistical methods
All randomised patients were considered eligible for inclusion 
in the analysis in accordance with the intention-to-treat anal-
ysis principle. In accordance with the provision specified in the 
statistical analysis plan, a negative binomial model was used for 
the analysis of data on consultation rates because of overdis-
persion that rendered the Poisson model inappropriate. The 
model included general practice as a fixed effect and accounted 
for additional variation due to repeat consultations by the same 
participant. The effect of clustering arising from couples being 
randomised together was explored by fitting the model using 
the method of generalised estimating equations. Compari-
sons between groups on continuous secondary endpoints were 
performed using a linear model that included general practice 
as a factor and the baseline value as a covariate (where appli-
cable). Comparisons between groups on categorical secondary 
endpoints were performed using logistic regression with general 
practice fitted as a factor. The analyses performed on the primary 
and secondary endpoints were repeated adjusting for additional 
baseline covariates (eg, number of consultations in 12 months 
prior to randomisation, gender, comorbidities, smoking status, 
MRC dyspnoea score) as part of a sensitivity analysis. A mixed 
model for repeated measures was applied to the scale scores 
from patient-reported outcomes and included covariates for 
general practice, treatment allocation, timepoint, baseline and a 
timepoint-by-treatment allocation interaction. Survival analysis 
methods (including the log-rank test and proportional hazards 
regression) were used to compare randomised groups on time to 
first consultation for a respiratory symptom from baseline.
Costs of delivering the CHEST intervention were calcu-
lated to include: identification of the at-risk population, invi-
tation processes, training to deliver the CHEST intervention, 
consultation time (assuming delivered by a practice nurse), 
spirometry equipment including laptop computer, and patient 
reminders. Total health service costs were derived by multi-
plying the resource used by the relevant MBS and PBS fee; 
these data included patient copayment contribution. Costs are 
reported as undiscounted cost for 2016. We calculated an incre-
mental cost-effectiveness ratio (ICER) per additional respiratory 
consultation. We performed sensitivity analyses including the 
costs of spirometry equipment as this was not a core part of the 
intervention.
resuLTs
Between 29 May 2013 and 19 November 2015, we approached 
2501 current and 2666 ex-smokers, and 112 with unclear quit 
status; 940 of these (17.8%) responded. Of these, 623 (66%) 
met our eligibility criteria and 551 (88%) consented to be 
randomised (see figure 1).
Table 1 presents baseline data on the trial cohort. Patients 
who did not respond to the initial trial invitation were similar in 
terms of age (mean 65.7 years) and sex (56.0% male) but were 
more likely to be current smokers (48.0% vs 42.6%). There was 
a higher proportion of current smokers in the control than inter-
vention group (46.6% vs 38.7%) but no other between-group 
imbalances. Three patients were diagnosed with lung cancer 
during the 12-month follow-up, two in the intervention group 
and one in the control group.
The primary outcome was determined for 542 participants 
(98.3%); 12-month questionnaire data were available on 416 
participants (intervention 212 (77%); control 204 (74%)). 
SYMPTOM questionnaires were completed for 88% of inter-
vention and 66% of control consultations.
Table 2 presents data on total GP consultations and those for 
respiratory symptoms. On average, the overall cohort consulted 
their GP approximately nine times over the 12-month follow-up 
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Table 4 HADS, cancer worry and AQoL-8D over time and between groups 
Month randomised group n Mean sd Min Max Ls mean
Ls Mean 
difference
Lower 
95% CL
upper 
95% CL
P-value for 
difference
P-value for 
difference rank 
analysis
Anxiety
  0 Control 268 5.6 4.1 0.0 21.0
  0 Intervention 269 5.7 3.9 0.0 21.0
  1 Control 223 5.3 4.2 0.0 18.0 5.5
  1 Intervention 234 5.3 4.0 0.0 20.0 5.3 −0.2 −0.7 0.3 0.3954 0.6054
  12 Control 204 5.2 4.2 0.0 18.0 5.6
  12 Intervention 212 5.3 4.1 0.0 19.0 5.4 −0.1 −0.6 0.4 0.6083 0.5179
Depression
  0 Control 268 4.4 3.8 0.0 20.0
  0 Intervention 269 4.1 3.4 0.0 19.0
  1 Control 223 4.3 4.1 0.0 21.0 4.2
  1 Intervention 234 3.9 3.5 0.0 16.0 3.9 −0.3 −0.7 0.1 0.1557 0.1218
  12 Control 204 4.4 4.1 0.0 21.0 4.2
  12 Intervention 212 3.9 3.5 0.0 19.0 4.0 −0.2 −0.7 0.2 0.3672 0.3344
Cancer worry
  0 Control 268 3.4 3.2 0.0 17.0
  0 Intervention 269 3.4 3.2 0.0 17.0
  1 Control 223 3.3 3.3 0.0 16.0 3.7
  1 Intervention 234 3.2 3.1 0.0 18.0 3.5 −0.2 −0.7 0.2 0.3381 0.4166
  12 Control 204 2.9 3.0 0.0 16.0 3.5
  12 Intervention 212 2.8 3.2 0.0 18.0 3.2 −0.3 −0.7 0.2 0.2436 0.1576
Quality of life
  0 Control 268 76.5 13.6 23.4 124.8
  0 Intervention 268 77.1 12.2 27.7 115.6
  1 Control 221 77.5 15.9 11.4 124.8 78.1
  1 Intervention 234 79.6 14.2 31.2 124.8 79.3 1.2 −0.9 3.2 0.2562 0.1915
  12 Control 203 77.2 14.5 20.6 124.8 78.1
  12 Intervention 213 79.1 15.1 27.0 124.8 78.8 0.7 −1.4 2.8 0.5111 0.5923
AQoL, Assessment of Quality of Life; CL, confidence limit; HADS, Hospital Anxiety and Depression Scale; LS, least square; Max, maximum; Min, minimum.
period, but the majority did not consult at all about respiratory 
symptoms (intervention 59.5% vs control 66.4%). In the negative 
binomial model, with trial group and practice site as covariates, 
there was a 40% relative increase in respiratory consultations 
in the intervention group: (adjusted rates (95% CI) interven-
tion 0.57 (0.47 to 0.70), control 0.41 (0.32 to 0.52), relative 
rate 1.40 (1.08 to 1.82); p=0.0123). This effect remained 
after adjusting for additional baseline covariates (table 3). In 
the negative binomial model, with trial group and practice site 
as covariates, there was no difference between groups on total 
consultation rates: (adjusted rates (95% CI), intervention 8.52 
(7.63 to 9.52), control 8.45 (7.51 to 9.50), relative rate 1.01 
(0.88 to 1.16); p=0.8998).
Table 4 presents the results of mixed model repeated measures 
analyses of HADS, cancer worry and AQoL-8D data. There were 
no statistically significant differences between trial groups in 
depression, general or cancer-specific anxiety, or quality of life. 
Table 5 shows that there were no significant differences between 
trial groups over time in perceived risk, self-efficacy to consult 
or knowledge of symptoms lung disease.
Table 6 presents the results on time from onset of respiratory 
symptom to GP consultation, for all consultations combined 
and for each serial consultation. Figure 2 presents the survival 
analysis curves for time to first respiratory consultation. In the 
survival analyses, there was no significant difference in time to 
first respiratory consultation (log-rank test : χ2 1.5923 (degrees 
of freedom (df) 1), p>χ2 0.207) or time to present for all consul-
tations (HR 0.827; 95% CI 0.64 to 1.07; p=0.147).
There were 46 chest X-rays ordered in the intervention group 
(mean 0.24 per person) and 50 in the control group (mean 0.25 
per person). We were unable to identify accurately all referrals 
to respiratory specialists. The cost of the CHEST intervention 
(base case) was $A207.77 (SD $A99.22) per participant in the 
intervention group. Based on the adjusted respiratory consulta-
tion rate at 12 months, this equates to an ICER per additional 
respiratory consultation of $A1289. In the sensitivity analysis, 
including the costs of spirometry equipment, the CHEST inter-
vention cost $A816.91 (SD $A606.75) per participant in the 
intervention group, with an ICER of $A5105 per additional 
respiratory consultation.
dIsCussIon
summary
This is the largest trial yet to test the effect of a behavioural inter-
vention to promote help-seeking in patients at increased risk of 
lung cancer. We demonstrated a statistically significant 40% 
relative increase in consultations about respiratory symptoms 
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Table 5 Perceived risk, self-efficacy and knowledge scores over time and between group 
Month
randomised 
group n Mean sd Min Max Ls mean
Ls mean 
difference
Lower 
95% CL
upper 
95% CL
P-value for 
difference
P-value for 
difference rank 
analysis
Perceived risk
  0 Control 268 6.9 1.9 0.0 10.0
  0 Intervention 269 6.9 1.7 0.0 10.0
  1 Control 223 6.7 2.0 0.0 10.0 6.8
  1 Intervention 234 7.0 1.7 2.0 10.0 7.1 0.2 −0.0 0.5 0.0728 0.0836
  12 Control 204 6.7 1.9 0.0 10.0 6.8
  12 Intervention 212 6.7 1.9 0.0 10.0 6.8 0.1 −0.2 0.3 0.6452 0.4904
Self-efficacy
  0 Control 268 85.0 24.2 0.0 110.0
  0 Intervention 269 87.3 24.6 0.0 110.0
  1 Control 222 89.1 21.7 0.0 110.0 89.8
  1 Intervention 234 92.4 19.6 7.0 110.0 92.2 2.4 −0.9 5.7 0.1583 0.1207
  12 Control 204 90.7 20.0 0.0 110.0 91.7
  12 Intervention 212 94.5 17.5 0.0 110.0 94.1 2.4 −1.0 5.9 0.1695 0.1683
Knowledge
  0 Control 268 9.0 5.4 −8.0 19.0
  0 Intervention 269 8.7 5.9 −10.0 19.0
  1 Control 223 9.4 5.4 −9.0 19.0 9.5
  1 Intervention 234 9.4 6.2 −13.0 21.0 9.6 0.1 −0.8 1.1 0.7769 0.4583
  12 Control 204 8.8 5.9 −11.0 19.0 8.9
  12 Intervention 212 9.7 6.1 −8.0 19.0 9.9 1.0 −0.0 2.0 0.0509 0.0271
CL, confidence limit; LS, least square; Max, maximum; Min, minimum.
Table 6 Time from symptom onset to consultation
Characteristic
Intervention
(n=274)
Control
(n=277)
All consultations: mean days 
(SD) (n)
66.99 (109.18) (107) 76.32 (102.31) (94)
Median days (min–max) 21 (1–365) 30 (2–365)
Appointment 1: mean (SD) (n) 62.5 (102.26) (76) 76.29 (102.52) (70)
Median days (min–max) 21 (2–365) 30 (2–365)
Appointment 2: mean (SD) (n) 71.22 (119.75) (23) 83.85 (111.74) (20)
Median days (min–max) 14 (3–365) 30 (2–365)
Appointment 3: Mean (SD) (n)    68 (132.63) (7) 39.25 (37.85) (4)
Median days (min–max) 7 (1–365) 30 (7–90)
Appointment 4: mean (SD) (n) 304 (-) (1) -
Median days (min–max) 304 (304–304) -
Figure 2 Survival curve for time from symptom onset to first 
consultation.
in those receiving the intervention but no overall increase in 
consultation rates. There was a non-significant mean reduction 
of 14 days in time to first presentation with respiratory symp-
toms. There was no evidence of psychological harm from the 
intervention.
Limitations
This was designed as a phase II efficacy trial of a complex inter-
vention.28 The primary outcome of respiratory consultation rates is 
based on the intervention logic model: by encouraging patients at 
increased risk of lung cancer to consult their GP when they develop 
respiratory symptoms, this would reduce the diagnostic delay of lung 
cancer and potentially result in the detection of earlier stage disease. 
Our primary outcome is, therefore, a suitable intermediate measure 
along this causal pathway. However, even in this population at 
increased risk of lung cancer, during a 12-month follow-up period, 
only three participants (0.54%) were diagnosed with lung cancer. 
It would require a substantially larger trial to be powered even to 
detect differences in time to diagnosis of lung cancer, let alone in 
clinical outcomes such as lung cancer stage or mortality. The control 
group received spirometry and a brief discussion about lung health. 
This was intended as an attention control but could potentially have 
also increased consultation rates for respiratory symptoms. There 
was also a chance imbalance between groups, with a higher propor-
tion of current smokers in the control group. Both of these limita-
tions could have reduced the estimated effect size of the CHEST 
intervention. We achieved a very low attrition rate for the primary 
outcome (98.3%), but we had greater loss-to-follow-up for the 
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patient-reported outcomes. In particular, there was greater attrition 
for responses to the SYMPTOM questionnaire in the control group. 
This might have biased our estimates of the effect of the interven-
tion on time to GP consultation but it is difficult to know in which 
direction.
Generalisability
We recruited patients from general practices in two large Austra-
lian cities and from suburbs with a range of socioeconomic depriva-
tion. Patients at increased risk of lung cancer are a ‘hard-to-reach’ 
group due to smoking stigma and socioeconomic deprivation. The 
response rate to the mailed invitation into the trial was 18% of 
whom only 66% were eligible. Our final accrual rate was 10.6%; 
while participants had a similar age and sex distribution to non-re-
sponders, there was a higher proportion of ex-smokers in the trial 
(60% vs 51% in the invited population). It is possible that there was 
a selection bias towards those with less severe respiratory disease 
given the low rate of baseline respiratory consultations and lung 
function results. It is difficult to know in which direction this bias 
might affect our estimate of the effect size of the CHEST interven-
tion. Current smokers may have greater barriers to consulting and 
therefore we might have seen a larger effect size in a less biased 
sample. Alternatively, those with more severe respiratory disease 
may be more frequent consulters at baseline, thereby reducing any 
potential effect on consultation rates.
Interpretation
Previous research in England found that patients at increased risk 
of lung cancer commonly have symptoms associated with lung 
cancer but many do not seek help about these symptoms.11 34 
Smokers in particular are less likely than non-smokers to consult 
their GP when they develop respiratory symptoms.16 Non-con-
sulters have higher tolerance for their symptoms, are more likely 
to self-manage and have greater concern about wasting their GP’s 
time.11 Qualitative research with GPs has questioned the value 
of mass media symptom awareness campaigns due to concerns 
about overwhelming the health system.35 Together, these find-
ings have led to calls for targeted interventions in primary care 
to improve symptom recognition and empower help-seeking in 
patients at increased risk of lung cancer.16 35
Our parallel qualitative evaluation of the CHEST trial 
confirmed the theoretical underpinning of the intervention: 
we found evidence of reduction in stigma and guilt, increase in 
salience and personal relevance of symptoms and sanctioning 
of help-seeking,15 which translated into increased respiratory 
consultations. Of interest, in the trial we found no difference in 
our quantitative measures of knowledge, self-efficacy to consult, 
risk perception or measures of general and cancer-specific 
anxiety. We measured anxiety as a potential harm of the inter-
vention. The theoretical models underpinning the CHEST inter-
vention did not suggest we needed to create anxiety to have an 
effect; indeed, fear of cancer can be a barrier to help-seeking.10 
The CHEST intervention did not alter overall consultation rates 
but had a specific effect on help-seeking for respiratory symp-
toms. Although it prompted more respiratory consultations, 
there was only a small reduction in the duration of symptoms 
before seeking help; an average of 14 days earlier for the first 
consultation and 9 days for all respiratory consultations. Partici-
pants in the intervention group took an average of 2 months from 
symptom onset to consult about a new respiratory symptom. 
This size of effect is unlikely to be of clinical significance. The 
intervention made it more likely that someone would present 
with respiratory symptoms, but further consideration is required 
on how to prompt even earlier presentation with these symp-
toms. It may be that additional interventions aimed at the GP 
are required. Patients with lung cancer often have multiple GP 
visits about respiratory symptoms before referral to a specialist 
for definitive diagnosis.36 By highlighting that these patients are 
at increased risk of lung cancer, they could potentially be inves-
tigated sooner by their GP and reduce the overall diagnostic 
interval.37
The CHEST intervention cost $A1289 per additional respi-
ratory consultation. In the absence of trial data with sufficient 
numbers of lung cancer cases, it is difficult to estimate the cost 
per lung case detected. If we assume that 3% of these consulta-
tions led to a diagnosis of lung cancer,38 this would equate to 
approximately $A42 500 per case detected.
Significant uncertainty therefore remains about the best 
strategies to promote earlier detection of lung cancer. The US 
Preventive Services Taskforce has recommended low-dose CT 
screening for adults aged 55 to 80 years with at least a 30 pack-
year smoking history.39 Other countries are still considering the 
evidence to inform national policy. In Australia, the cost-effec-
tiveness of lung cancer CT screening is estimated at $A2 33 000 
per quality-adjusted life-year gained, making it less likely to be 
implemented in the near future.21 There are other limitations 
of focusing on low-dose CT screening as the main strategy for 
early detection of lung cancer. Low-dose CT is more effective at 
detecting parenchymal lung tumours and can miss small endo-
bronchial cancers40 which are common among smokers and can 
potentially produce early symptoms. Interval lung cancers occur 
even with annual CT screening and will present symptomatically 
at a more advanced stage.41 Even within the context of national 
cancer screening programmes for breast and bowel cancer, the 
majority of these cancers are not detected via screening, due to 
low participation rates and interval cancers.42
A key implementation challenge for CT screening is the 
identification of the screening population.22 The findings of 
the CHEST Australia trial should perhaps be considered in the 
broader context of respiratory disease management in primary 
care including lung cancer and COPD. International guidelines 
currently do not recommend screening for COPD, but instead 
suggest a case-finding approach in patients at risk of the condi-
tion who have respiratory symptoms.43 44 The CHEST interven-
tion could therefore be a way to identify patients at increased risk 
of either lung cancer or COPD and include spirometry as part 
of a respiratory health consultation. In those at very high risk 
of lung cancer (eg, more than 30 pack-years smoking history), 
low-dose CT screening would be recommended in some coun-
tries. For those at moderate risk of lung cancer, the behavioural 
CHEST intervention could raise patient awareness of respiratory 
symptoms, reduce stigma and promote help-seeking. This could 
potentially improve the management of COPD and prompt 
earlier assessment by their GP for lung cancer. The CHEST 
intervention is a relatively low-cost option which might have 
broader implications for improving the management of respira-
tory symptoms, and serious lung disease, in primary care.
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